CURAGEN CORP|4Oct 5, 4:20 PM ET

CURAGEN CORP 4

4 · CURAGEN CORP · Filed Oct 5, 2009

Form 4

Period: 2009-10-01

Director

Transactions

Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-10-01−35,000→ 0 total
Exercise: $0.57Exp: 2010-10-01→ Common Stock (35,000 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-10-01−17,500→ 0 total
Exercise: $1.09Exp: 2010-10-01→ Common Stock (17,500 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-10-01−15,000→ 0 total
Exercise: $2.73Exp: 2010-10-01→ Common Stock (15,000 underlying)
Disposition to Issuer
Common Stock
2009-10-01−10,000→ 0 total
Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-10-01−17,500→ 0 total
Exercise: $0.69Exp: 2010-10-01→ Common Stock (17,500 underlying)

Footnotes (5)

[F1]Disposed of pursuant to merger agreement between issuer and Celldex Therapeutics, Inc. in exchange for 2,739 shares of Celldex Therapeutics, Inc. common stock having a market value of $19.82 per share on the effective date of the merger, October 1, 2009.
[F2]This option, which vested 100% on May 2, 2007, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 4,108 shares of Celldex Therapeutics, Inc. common stock for $9.97 per share.
[F3]This option, which vested 100% on January 24, 2008, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 4,793 shares of Celldex Therapeutics, Inc. common stock for $2.52 per share.
[F4]This option, which vested 100% on May 21, 2008, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 4,793 shares of Celldex Therapeutics, Inc. common stock for $3.98 per share.
[F5]This option, which vested 100% on February 11, 2009, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 9,586 shares of Celldex Therapeutics, Inc. common stock for $2.08 per share.

Documents

1 file